Valuation: RenovoRx, Inc.

Market Cap 61.83M 55.24M 51.54M 46.81M 88.17M 5.98B 88.83M 619M 242M 3.04B 232M 227M 9.78B P/E 2026 *
-5.27x
P/E 2027 * -9.79x
Enterprise Value 61.83M 55.24M 51.54M 46.81M 88.17M 5.98B 88.83M 619M 242M 3.04B 232M 227M 9.78B EV / Sales 2026 *
16x
EV / Sales 2027 * 5.41x
Free-Float
96.41%
Yield 2026 *
-
Yield 2027 * -
08-25 RenovoRx Publishes Pharmacokinetic and Pharmacodynamic Data Supporting Tamp Platform?s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer CI
08-24 RenovoRx, Inc., Q2 2026 Earnings Call, Aug 12, 2026
08-20 RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath, an Advanced Dual-Occlusion Catheter for Targeted Therapeutic Drug-Delivery for Cancer Treatment CI
08-13 RenovoRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-13 Renovorx, Inc. Increases Earnings Guidance for Full Year 2026 CI
08-11 RenovoRx Achieves Full Enrollment in Phase III Tiger-Pac Trial for Locally Advanced Pancreatic Cancer CI
08-06 RenovoRx Announces First Commercial Clinical Use Of RenovoCath In Sarcoma Patient Treatment CI
08-06 Renovorx Inc and Carti Cancer Center Announce First Commercial Clinical Use of Renovocath in Sarcoma Patient Treatment CI
06-23 RenovoRx, Inc. Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026, Jun-23-2026 12:30 PM
06-11 RenovoRx Announces Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP In Locally Advanced Pancreatic Cancer CI
06-02 RenovoRx, Inc., Q1 2026 Earnings Call, May 14, 2026
05-28 RenovoRx gets FDA orphan drug designation for oxaliplatin to treat pancreatic cancer RE
05-26 Renovorx Publishes Pharmacokinetic and Pharmacodynamic Sub-Study Results from Ongoing Phase III TIGeR-PaC Clinical Trial Evaluating Tamp Platform for Targeted Intra-Arterial Delivery of Gemcitabine CI
1 day-1.44%
1 week-12.18%
Current month-12.18%
1 month-42.68%
3 months+47.71%
6 months+52.22%
Current year+63.08%
1 week 1.28
Extreme 1.275
1.61
1 month 1.28
Extreme 1.275
2.3
Current year 0.77
Extreme 0.77
2.59
1 year 0.7
Extreme 0.7006
2.59
3 years 0.53
Extreme 0.5306
2.59
5 years 0.53
Extreme 0.5306
12.51
10 years 0.53
Extreme 0.5306
16.74
Manager TitleAgeSince
Chief Executive Officer 49 27/10/2014
Chief Tech/Sci/R&D Officer 60 01/12/2009
Director of Finance/CFO 71 03/02/2026
Director TitleAgeSince
Director/Board Member 82 01/12/2012
Chairman 60 01/05/2018
Director/Board Member 84 01/01/2012
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Free

Director

55,924 0.1239%
01/10/26 Free

Director

55,924 0.1239%
01/10/26 Free

Director

55,924 0.1239%
Change 5-day change 1-year change 3-year change Capi.($)
-1.44%-12.18%+12.30%+16.10% 61.83M
+0.58%-0.10%-25.78%+1.91% 171B
-1.81%-0.90%-13.04%+12.34% 109B
-1.01%+0.00%-25.41%+3.59% 106B
-1.77%-0.38%-48.31%-11.79% 75.43B
+0.28%+5.66%+2.77%+72.56% 60.54B
-0.44%+6.13%+10.95%+65.67% 53.16B
-0.08%+0.65%-6.42%-31.35% 49.07B
-1.70%-2.97%-19.23%+13.61% 39.92B
+1.09%-2.31%+27.67%+1.30% 31.81B
Average +0.01%-0.48%-8.45%+14.39% 69.59B
Weighted average by Cap. +0.22%+0.68%-16.69%+11.64%

Financials

2026 *2027 *
Net sales 3.87M 3.46M 3.23M 2.93M 5.52M 375M 5.56M 38.79M 15.16M 191M 14.54M 14.22M 612M 11.43M 10.22M 9.53M 8.66M 16.31M 1.11B 16.43M 115M 44.75M 563M 42.92M 42M 1.81B
Net income -12M -10.72M -10M -9.09M -17.11M -1.16B -17.24M -120M -46.97M -590M -45.05M -44.08M -1.9B -7.01M -6.27M -5.85M -5.31M -10M -678M -10.07M -70.25M -27.44M -345M -26.33M -25.76M -1.11B
Net Debt - -
Projected Income Statement - Annual - RenovoRx, Inc.
Logo RenovoRx, Inc.
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
Employees
-
Date Price Change Volume
07/10/26 $1.370 -1.44% 594,618
06/10/26 $1.390 -5.44% 621,682
05/10/26 $1.470 -6.96% 618,033
02/10/26 $1.580 +1.94% 269,370
01/10/26 $1.550 -0.64% 404,025
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - RenovoRx, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.370USD
Average target price
7.125USD
Spread / Average Target
+420.07%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - RenovoRx, Inc.
  1. Stock Market
  2. Stocks
  3. RNXT Stock